XPO1 and non-small cell lung carcinoma: Therefore, we evaluated the impact of XPO1 inhibition (XPO1i) on the steady-state level of cytoplasmic EZH2 by using the XPO1-specific inhibitor selinexor in the A549 non-small cell lung cancer (NSCLC) cell line, which expresses DLC1 mRNA but lacks readily detectable DLC1 protein4.